BACKGROUND: MitraClip therapy is increasingly used in patients deemed inoperable to treat severe mitral regurgitation (MR), but long-tern data is scarce. AIMS: The multicentre, industry-independent German Transcatheter Mitral Valve Interventions (TRAMI) registry comprises the largest prospectively enrolled cohort of patients treated by MitraClip therapy. The current analysis is focusing on long-term mortality rates, cardiac rehospitalization and reintervention. METHODS AND RESULTS: Long-term follow-up (median time 1037 days) in the TRAMI registry was available for 722 patients treated at 20 German centres. Improvements in New York Heart Association (NYHA) functional class (I/II long-term: 65% vs. 1-year follow-up: 63.3%) and self-rated health-status (EuroQuol visual analogue scale [EQ VAS] long-term: 60 [50-70] vs. 1-year follow-up: 60 [50; 70]) were pertained over time. Estimated mortality rates by Kaplan-Meier method were 19.7% for 1-year, 31.9% for 2-year and 53.1% for 4-year follow-up without differences found for MR aetiology. Multivariable Cox-regression analysis identified previous aortic valve implantation (hazard ratio [HR] = 2.21; p < 0.0001), NYHA class IV (HR = 1.78; p < 0.001), prior cardiac decompensation (HR = 1.63; p < 0.001), creatinine > 1.5 mg/dl (HR = 1.63; p < 0.0001) and left ventricular ejection fraction < 30% (HR = 1.60; p < 0.001) as most predictive for long-term mortality. CONCLUSIONS: Long-term outcome in the TRAMI registry confirmed lasting clinical improvements and low intervention rates. Long-term mortality was strongly influenced by cardiac and non-cardiac co-morbidities and was found comparable for both MR aetiologies.
BACKGROUND: MitraClip therapy is increasingly used in patients deemed inoperable to treat severe mitral regurgitation (MR), but long-tern data is scarce. AIMS: The multicentre, industry-independent German Transcatheter Mitral Valve Interventions (TRAMI) registry comprises the largest prospectively enrolled cohort of patients treated by MitraClip therapy. The current analysis is focusing on long-term mortality rates, cardiac rehospitalization and reintervention. METHODS AND RESULTS: Long-term follow-up (median time 1037 days) in the TRAMI registry was available for 722 patients treated at 20 German centres. Improvements in New York Heart Association (NYHA) functional class (I/II long-term: 65% vs. 1-year follow-up: 63.3%) and self-rated health-status (EuroQuol visual analogue scale [EQ VAS] long-term: 60 [50-70] vs. 1-year follow-up: 60 [50; 70]) were pertained over time. Estimated mortality rates by Kaplan-Meier method were 19.7% for 1-year, 31.9% for 2-year and 53.1% for 4-year follow-up without differences found for MR aetiology. Multivariable Cox-regression analysis identified previous aortic valve implantation (hazard ratio [HR] = 2.21; p < 0.0001), NYHA class IV (HR = 1.78; p < 0.001), prior cardiac decompensation (HR = 1.63; p < 0.001), creatinine > 1.5 mg/dl (HR = 1.63; p < 0.0001) and left ventricular ejection fraction < 30% (HR = 1.60; p < 0.001) as most predictive for long-term mortality. CONCLUSIONS: Long-term outcome in the TRAMI registry confirmed lasting clinical improvements and low intervention rates. Long-term mortality was strongly influenced by cardiac and non-cardiac co-morbidities and was found comparable for both MR aetiologies.
Authors: S Heyl; B Luu; M Wieszner; A Nikkhoo; F Seeger; K Hemmann; B Assmus; B Kaess; A M Zeiher; C Walther; S Fichtlscherer; J Honold Journal: Int J Cardiol Heart Vasc Date: 2020-10-12
Authors: Dan Haberman; Rodrigo Estévez-Loureiro; Tomas Benito-Gonzalez; Paolo Denti; Dabit Arzamendi; Marianna Adamo; Xavier Freixa; Luis Nombela-Franco; Pedro Villablanca; Lian Krivoshei; Neil Fam; Konstantinos Spargias; Andrew Czarnecki; Isaac Pascual; Fabien Praz; Doron Sudarsky; Arthur Kerner; Vlasis Ninios; Marco Gennari; Ronen Beeri; Leor Perl; Haim Danenberg; Lion Poles; Sara Shimoni; Sorel Goland; Berenice Caneiro-Queija; Salvatore Scianna; Igal Moaraf; Davide Schiavi; Claudia Scardino; Noé Corpataux; Julio Echarte-Morales; Michael Chrissoheris; Estefanía Fernández-Peregrina; Mattia Di Pasquale; Ander Regueiro; Carlos Vergara-Uzcategui; Andres Iñiguez-Romo; Felipe Fernández-Vázquez; Danny Dvir; Maurizio Taramasso; Mony Shuvy Journal: J Clin Med Date: 2021-04-22 Impact factor: 4.241
Authors: Maximilian Spieker; Jonathan Marpert; Shazia Afzal; Daniel Scheiber; Florian Bönner; Patrick Horn; Malte Kelm; Ralf Westenfeld Journal: Int J Cardiol Heart Vasc Date: 2021-06-03
Authors: Mischa Külling; Roberto Corti; Georg Noll; Silke Küest; David Hürlimann; Christophe Wyss; Ivano Reho; Felix C Tanner; Jeremy Külling; Nicolai Meinshausen; Oliver Gaemperli; Peter Wenaweser; Sacha P Salzberg; Thierry Aymard; Jürg Grünenfelder; Patric Biaggi Journal: Open Heart Date: 2020-07
Authors: Michael G Paulus; Christine Meindl; Lukas Böhm; Magdalena Holzapfel; Michael Hamerle; Christian Schach; Lars S Maier; Kurt Debl; Bernhard Unsöld; Christoph Birner Journal: PLoS One Date: 2020-05-28 Impact factor: 3.240
Authors: Matthias Koschutnik; Varius Dannenberg; Carolina Donà; Christian Nitsche; Andreas A Kammerlander; Sophia Koschatko; Daniel Zimpfer; Martin Hülsmann; Stefan Aschauer; Matthias Schneider; Philipp E Bartko; Georg Goliasch; Christian Hengstenberg; Julia Mascherbauer Journal: J Pers Med Date: 2022-01-11